Concepedia

Karen A. Maegley

KA

Statistics

Publications

33

Citations

3K

H-Index

25

Active since

1991

Affiliations

Pfizer (United States)(Current)

Newcastle University

Bone Therapeutics

Howard Hughes Medical Institute

Karen A. Maegley is an author at Pfizer (United States) specializing in pharmacology, medicinal chemistry, and molecular biology.

Publications per year

1991–2023

33

Publications

33

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Christopher Calabrese, Robert J. Almassy, Stephen Barton et al. · JNCI Journal of the National Cancer Institute · 2004 · 485 citations · Full text

, , +15

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Huw D. Thomas, Christopher Calabrese, Michael A. Batey et al. · Molecular Cancer Therapeutics · 2007 · 302 citations

, , +15

Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase

Alex W. White, Robert J. Almassy, A. Hilary Calvert et al. · Journal of Medicinal Chemistry · 2000 · 287 citations · Full text

, , +16

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

Alexei Brooun, K.S. Gajiwala, Ya‐Li Deng et al. · Nature Communications · 2016 · 160 citations · Full text

, , +17

Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors

Donald J. Skalitzky, Joseph Marakovits, Karen A. Maegley et al. · Journal of Medicinal Chemistry · 2002 · 152 citations · Full text

, , +16

1–5 of 33